Weight Watchers Broadens GLP-1 Reach As Eli Lilly Pursues New Kidney Disease Therapies

All NewsJune 4, 2026

Weight Watchers joins LillyDirect for GLP-1 access as Eli Lilly signs a kidney disease research pact with Ascidian worth up to $1.9 billion.

Importance Rank:

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT